Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Teleflex Incorporated (TFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TFX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $140.11
1 Year Target Price $140.11
| 0 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.23% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.37B USD | Price to earnings Ratio 28.32 | 1Y Target Price 140.11 |
Price to earnings Ratio 28.32 | 1Y Target Price 140.11 | ||
Volume (30-day avg) 14 | Beta 1.08 | 52 Weeks Range 108.60 - 247.49 | Updated Date 08/15/2025 |
52 Weeks Range 108.60 - 247.49 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 1.11% | Basic EPS (TTM) 4.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 3.36 | Actual 3.73 |
Profitability
Profit Margin 6.31% | Operating Margin (TTM) 24.16% |
Management Effectiveness
Return on Assets (TTM) 5.41% | Return on Equity (TTM) 4.36% |
Valuation
Trailing PE 28.32 | Forward PE 8.77 | Enterprise Value 7110881265 | Price to Sales(TTM) 1.77 |
Enterprise Value 7110881265 | Price to Sales(TTM) 1.77 | ||
Enterprise Value to Revenue 2.34 | Enterprise Value to EBITDA 11.82 | Shares Outstanding 44192800 | Shares Floating 44032397 |
Shares Outstanding 44192800 | Shares Floating 44032397 | ||
Percent Insiders 0.33 | Percent Institutions 108.46 |
Upturn AI SWOT
Teleflex Incorporated
Company Overview
History and Background
Teleflex Incorporated was founded in 1943 as a manufacturer of mechanical remote control systems. Over the years, it has transformed into a global provider of medical technology products.
Core Business Areas
- Vascular Solutions: Offers a range of products for vascular access, angiography, and thrombectomy procedures.
- Interventional Urology: Develops and markets devices for urological procedures, including BPH management.
- Surgical Solutions: Provides surgical instruments and devices for various surgical specialties.
- Anesthesia: Offers airway management, pain management, and respiratory care products.
- Interventional Access: Manufactures products for percutaneous procedures, including PICCs and central venous catheters.
Leadership and Structure
Liam Kelly serves as the Chairman, President, and Chief Executive Officer. Teleflex operates with a divisional structure, each focused on specific product categories.
Top Products and Market Share
Key Offerings
- Arrow EZ-IO: An intraosseous vascular access system used for rapid fluid and medication delivery. Significant market share in emergency and critical care settings. Competitors include Vidacare (Teleflex acquired), Pyng Medical.
- UroLift System: A minimally invasive procedure for treating benign prostatic hyperplasia (BPH). Gaining market share in the BPH treatment market. Competitors include Boston Scientific (Rezu016bm), Olympus (TURP, laser therapies).
- LMA Airway Products: Laryngeal masks used in anesthesia. Teleflex claims to have the airway management product in the world. Competitors include Medtronic.
Market Dynamics
Industry Overview
The medical technology industry is experiencing growth driven by aging populations, technological advancements, and increasing demand for minimally invasive procedures.
Positioning
Teleflex is a mid-sized player within the medical technology industry, focusing on niche markets and innovative solutions. Its competitive advantages include a diverse product portfolio and a strong distribution network.
Total Addressable Market (TAM)
The global medical device market size was valued at USD 550 billion in 2022 and is projected to reach USD 850 billion by 2030. Teleflex is positioned to capture a portion of this TAM through its focused product portfolio and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong distribution network
- Focus on innovation
- Established brand reputation
- Strategic acquisitions
Weaknesses
- Reliance on key products
- Exposure to reimbursement pressures
- Competition from larger medical device companies
- Integration risks from acquisitions
Opportunities
- Expanding into emerging markets
- Developing new technologies
- Acquiring complementary businesses
- Increasing adoption of minimally invasive procedures
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Product liability claims
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- MDT
- BSX
- BDX
Competitive Landscape
Teleflex competes with larger medical device companies by focusing on niche markets and offering specialized solutions. Its competitive advantages include a strong brand reputation and a diverse product portfolio.
Major Acquisitions
Standard Bariatrics
- Year: 2022
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expanded its presence in the bariatric surgery market, offering innovative devices for weight management procedures.
Growth Trajectory and Initiatives
Historical Growth: Teleflex has achieved consistent growth through organic initiatives and strategic acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for Teleflex, driven by its innovative product portfolio and expanding market presence.
Recent Initiatives: Recent initiatives include the acquisition of Standard Bariatrics, expanding presence in the bariatric surgery market
Summary
Teleflex is a strong medical technology company with a diverse product portfolio and a history of growth through acquisitions. It benefits from a focus on niche markets and innovative solutions. Teleflex needs to be wary of competition from larger players and potential integration risks from acquired companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Investor presentations
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Teleflex Incorporated
Exchange NYSE | Headquaters Wayne, PA, United States | ||
IPO Launch date 1988-02-18 | Chairman, President & CEO Mr. Liam J. Kelly | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 14100 | Website https://www.teleflex.com |
Full time employees 14100 | Website https://www.teleflex.com | ||
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.